PCM
BVS icon

Prelude Capital Management’s Bioventus BVS Stock Holding History

Prelude Capital Management’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$123K Sell
13,432
-3,718
-22% -$31.2K 0.01% 1014
2025
Q4 		$128K Buy
17,150
+6,160
+56% +$44.3K 0.01% 1149
2025
Q3 		$73.5K Buy
+10,990
New +$76.3K 0.01% 1081
2025
Q2 		– Sell
-19,916
Closed -$182K – 1032
2025
Q1 		$182K Buy
19,916
+1,682
+9% +$16.8K 0.01% 962
2024
Q4 		$191K Sell
18,234
-8,757
-32% -$104K 0.01% 1008
2024
Q3 		$323K Buy
+26,991
New +$233K 0.02% 828

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prelude Capital Management's BVS Position: Q1 2026 in Review

Prelude Capital Management reduced its Bioventus (BVS) stake by 22% in Q1 2026, selling an estimated $31.2K and leaving 13,432 shares worth $123K. The position accounts for 0.01% of the portfolio, ranked #1014.

Prelude Capital Management first reported a position in BVS in Q3 2024 and has held it in 6 quarters since. The position peaked at $323K in Q3 2024. 157 funds tracked by Wall St. Rank hold BVS as of Q1 2026.

  • Prelude Capital Management held 13,432 shares of Bioventus worth $123K as of Q1 2026.
  • Prelude Capital Management sold 3,718 Bioventus shares in Q1 2026, an estimated $31.2K.
  • Bioventus made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1014 holding.
  • Prelude Capital Management first reported a position in Bioventus in Q3 2024 and has held it in 6 quarters since.
  • Prelude Capital Management's Bioventus position peaked at $323K in Q3 2024.
  • 157 funds tracked by Wall St. Rank held Bioventus as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.